Combination Bevacizumab and Verteporfin (Two Different Sequences of Treatment)in Neovascular AMD
Completed · Phase 2
Conditions studied: Choroidal Neovascularization, Macular Degeneration
In brief
The purpose of this research study is to compare different timing therapies of Verteporfin with Bevacizumab to treat choroidal neovascularization (CNV) due to age-related macular degeneration (AMD).
Key facts
- Study ID
- NCT00426998
- Run by
- Retinal Consultants Medical Group
- People needed
- 30
- Starts
- 2006-04-01
- Last updated by the study team
- 2007-01-26
Who can join
Age: 55 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Patients are men or women of age 55 or older
- Patients have subfoveal CNV due to AMD with lesion size less than or equal to 9 MPS DA
- patients have not received previous treatment for subfoveal CNV due to AMD.
- Patients have a visual acuity between 20/40 and 20/320-
You may not qualify if…
- Subjects who have received previous treatment for subfoveal CNV, in their study eye including prior PDT, transpupillary thermotherapy (TTT), submacular surgery, drug therapies such as Macugen or other anti-angiogenic compounds, or other local treatment. Previous laser photocoagulation therapy is acceptable, provided it was not subfoveal.
- Patients with a known hypersensitivity/allergy to verteporfin, porfimer sodium, or other porphyrins, porphyria or other porphyrin sensitivity, or hypersensitivity to sunlight or bright artificial light.
- Patients who use medications that may induce photosensitivity.
- Patients who have undergone YAG capsulotomy within the last month.
- Subjects currently involved in any experimental procedure within the last 12 weeks.
- Female patients who are pregnant, fecund or breast-feeding.
Where it is running
- Retinal Consultants Medical Group, Inc. — Sacramento, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.